We did them - I'd just say ask our nurse about "minimally invasive" and few side effects - she would have laughed. Compared to surgical removal - I guess. Compared to short course RT... nah... Is it different and marketable? Yes.
I have no doubt cancer outcomes in IR disease will be inferior to RT today and for the next 5-10 years. But I've also written on how nadirs with focal treatments have clearly improved decade over decade and we need to have large institutions running active trials against this approach or we run a real risk of an inferior approach (my opinion today) gaining significant market share.
And just to be clear - repeat procedures and initial rises often don't count - read the data closely. RT has simply gotten very good - 95%+ cures with very low toxicity.
@TonyFelefly@PDBrownOnc@SahgalArjun@safaviaa@jryckman3 The marginal miss is always a relative high risk area - but better imaging, better plans, and better salvage drugs constantly shrink the value of that "extra". I don't doubt the relatively "current" data, but time will compress the effects. Like it has everywhere else.
@DBarreiro4 There's actually a good article I ref in this more complete review - the answer was - you just can NOT just tighten it up - over 2000 SBRT patients. Full substack discussing phoenix here - now 3.5 yrs old - likely new data but much of it still lands.
https://t.co/9MAAOqa9QX
@jryckman3@ESTRO_RT@ASTRO_org had a partner in rad in LR that would do kypho on quite a few - still don't think this is standard right? But I agree with your thinking.
@TonyFelefly@dr_coops I'd wager on both shift and some true hr reduction. But as I've argued for years, as the control moves north, there is less and less benefit of any HR shift. Why I often land on less ADT in many cases.
The march towards more (relative) dose in what in see and less dose elsewhere continues. All sites - everywhere - our Singularity. When HN and breast collapse, many more will fully appreciate the path.
For those following along - progressed to a one shot prompt is now where we are - we'll see how this holds up DASL-HiCaP prediction for ESMO.
See feed or highlights etc for more info on the framework.
@cpeedell@TonyFelefly@DrSpratticus Thanks. I used many experts here on x - many are named including two of Spratts threads. I thought our community did a really nice job addressing issues.
@SprakerMDPhD Capex expense. Income moves but so does debt and costs. Like my wife saving money buying some expensive item with a coupon. Here not close. You'd simply loose money faster shifting to protons. Not as fast as if protons paid equal to photons, but faster than photons.
@MohitKasibhatla Just sayin - you realize this "pointless" weekly monitoring is largest component for about 1/3rd pro rad onc fees via a single code?
I actually think the monitoring is very valuable during tx course. To me, during course adjustments were a critical part of the week.
@StrijbosMichiel They have a structured HIPPA BAA path via Cursor. So yes, as much as I trust "Epic" or probably any of the 15-20 vendors that admin (behind doors far from MDs) signs away access for "billing" or "dashboards" or "call centers" - yep - I'm good.
If I were still practicing, I'd have a single Grok bot assigned per patient - tracking every new input - monitoring everything added to the chart. Daily report - obviously checked and verified by a review bot.
IT would be getting a daily visit until this was approved.